Advertisement

Dipeptidyl Peptidases and Inflammatory Bowel Disease

  • Catherine A Abbott
  • Roger Yazbeck
  • Mark S Geier
  • Hans-Ulrich Demuth
  • Gordon S Howarth
Part of the Advances in Experimental Medicine and Biology book series (volume 575)

Keywords

Proliferate Cell Nuclear Antigen Dextran Sodium Sulphate Distal Colon Disease Activity Index Dipeptidyl Peptidase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alavi K, Schwartz MZ, Palazzo JP and Prasad R, 2000, Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2. J Pediatr Surg. 35: 847–851.CrossRefPubMedGoogle Scholar
  2. Boushey RP, Yusta B and Drucker DJ, 1999, Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Am J Physiol. 277: E937–E947.PubMedGoogle Scholar
  3. Brubaker PL, Crivici A, Izzo A, Ehrlich P, Tsai CH and Drucker DJ, 1997, Circulating and tissue forms of the intestinal growth factor, glucagon-like peptide-2. Endocrinology. 138: 4837–4843.CrossRefPubMedGoogle Scholar
  4. Drucker DJ, 2001, Glucagon-like peptide 2. J Clin Endocrinol Metab. 86: 1759–1764.CrossRefPubMedGoogle Scholar
  5. Drucker DJ, Lovshin J, Baggio L, Nian M, Adatia F, Boushey RP, Liu Y, Saleh J, Yusta B and Scrocchi L, 2000, New developments in the biology of the glucagon-like peptides GLP-1 and GLP-2. Ann N Y Acad Sci. 921: 226–232.PubMedCrossRefGoogle Scholar
  6. Drucker DJ, Shi Q, Crivici A, Sumner-Smith M, Tavares W, Hill M, DeForest L, Cooper S and Brubaker PL, 1997, Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat Biotechnol. 15: 673–677.CrossRefPubMedGoogle Scholar
  7. Egger B, Bajaj-Elliott M, MacDonald TT, Inglin R, Eysselein VE and Buchler MW, 2000, Characterisation of acute murine dextran sodium sulphate colitis: cytokine profile and dose dependency. Digestion. 62: 240–248.CrossRefPubMedGoogle Scholar
  8. Foltz M, Meyer A, Theis S, Demuth H-U and Daniel H, 2004, A rapid in vitro screening for delivery of peptidederived peptidase inhibitors as potential drug candidates via epithelial peptide transporters. J Pharmacol Exp Therap. 310: 695–702.CrossRefGoogle Scholar
  9. Geier MS, Tenikoff D, Yazbeck R, McCaughan GW, Abbott CA and Howarth GS, 2005, Development and resolution of experimental colitis in mice with targeted deletion of dipeptidyl peptidase IV. J Cell Physiol. 204: 687–692.CrossRefPubMedGoogle Scholar
  10. Hanauer SB and Baert F, 1994, Medical therapy of inflammatory bowel disease. Med Clin North Am. 78: 1413–1426.PubMedGoogle Scholar
  11. Hartmann B, Harr MB, Jeppesen PB, Wojdemann M, Deacon CF, Mortensen PB and Holst JJ, 2000a, In vivo and in vitro degradation of glucagon-like peptide-2 in humans. J Clin Endocrinol Metab. 85: 2884–2888.CrossRefPubMedGoogle Scholar
  12. Hartmann B, Thulesen J, Hare KJ, Kissow, H, Orskov C, Poulsen SS and Holst JJ, 2002, Immunoneutralization of endogenous glucagon-like peptide-2 reduces adaptive intestinal growth in diabetic rats. Regulatory Peptides. 105: 173–179.CrossRefPubMedGoogle Scholar
  13. Hartmann B, Thulesen J, Kissow H, Thulesen S, Orskov C, Ropke C, Poulsen SS and Holst JJ, 2000b, Dipeptidyl peptidase IV inhibition enhances the intestinotrophic effect of glucagon-like peptide-2 in rats and mice. Endocrinology. 141: 4013–4020.CrossRefPubMedGoogle Scholar
  14. Howarth GS, Xian CJ and Read LC, 2000, Predisposition to colonic dysplasia is unaffected by continuous administration of insulin-like growth factor-I for twenty weeks in a rat model of chronic inflammatory bowel disease. Growth Factors. 18: 119–133.PubMedCrossRefGoogle Scholar
  15. Jeppesen PB, Hartmann B, Thulesen J, Graff J, Lohmann J, Hansen BS, Tofteng F, Poulsen SS, Madsen JL, Holst JJ and Mortensen PB, 2001, Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology. 120: 806–815.CrossRefPubMedGoogle Scholar
  16. Jeppesen PB, Hartmann B, Thulesen J, Hansen BS, Holst JJ, Poulsen SS and Mortensen PB, 2000, Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon. Gut. 47: 370–376.CrossRefPubMedGoogle Scholar
  17. Kullmann F, Messmann H, Alt M, Gross V, Bocker T, Scholmerich J and Ruschoff J, 2001, Clinical and histopathological features of dextran sulfate sodium induced acute and chronic colitis associated with dysplasia in rats. Int J Colorectal Disease. 16: 238–246.CrossRefGoogle Scholar
  18. Munroe DG, Gupta AK, Kooshesh F, Vyas TB, Rizkalla G, Wang H, Demchyshyn L, Yang ZJ, Kamboj RK, Chen H, McCallum K, Sumner-Smith M, Drucker DJ and Crivici A, 1999, Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc Natl Acad Sci USA. 96: 1569–1573.CrossRefPubMedGoogle Scholar
  19. Murthy SN, Cooper HS, Shim H, Shah RS, Ibrahim SA and Sedergran DJ, 1993, Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Dig Dis Sci. 38: 1722–1734.CrossRefPubMedGoogle Scholar
  20. Rutgeerts P, Van Deventer S and Schreiber S, 2003, Review article: the expanding role of biological agents in the treatment of inflammatory bowel disease—focus on selective adhesion molecule inhibition. Alimentary Pharmacology & Therapeutics. 17: 1435–1450.CrossRefGoogle Scholar
  21. Scott RB, Kirk D, MacNaughton WK and Meddings JB, 1998, GLP-2 augments the adaptive response to massive intestinal resection in rat. Am J Physiol. 275: G911–G921.PubMedGoogle Scholar
  22. Sigalet DL and Martin GR, 2000, Hormonal therapy for short bowel syndrome. J Pediatr Surg. 35: 360–363.CrossRefPubMedGoogle Scholar
  23. Thulesen J, Knudsen LB, Hartmann B, Hastrup S, Kissow H, Jeppesen PB, Orskov C, Holst JJ and Poulsen SS, 2002, The truncated metabolite GLP-2 (3-33) interacts with the GLP-2 receptor as a partial agonist. Regulatory Peptides. 103: 9–15.CrossRefPubMedGoogle Scholar
  24. Tsai CH, Hill M, Asa SL, Brubaker PL and Drucker DJ, 1997, Intestinal growth-promoting properties of glucagonlike peptide-2 in mice. Am J Physiol. 273: E77–E84.PubMedGoogle Scholar
  25. Vowinkel T, Kalogeris TJ, Mori M, Krieglstein CF and Granger DN, 2004, Impact of dextran sulfate sodium load on the severity of inflammation in experimental colitis. Digestive Diseases & Sciences. 49: 556–564.CrossRefGoogle Scholar
  26. Xiao Q, Boushey RP, Cino M, Drucker DJ and Brubaker PL, 2000, Circulating levels of glucagon-like peptide-2 in human subjects with inflammatory bowel disease. Am J Physiol Regul Integr Comp Physiol. 278: R1057–R1063.PubMedGoogle Scholar
  27. Yamazaki, K., Yasuda, N., Inoue, T., Nagakura, T., Kira, K., Saeki, T. and Tanaka, I. (2004) The combination of metformin and a dipeptidyl peptidase IV inhibitor prevents 5-fluorouracil-induced reduction of small intestine weight. Eur J Pharmacol 488: 213–8.CrossRefPubMedGoogle Scholar
  28. Yusta, B., Boushey, R.P. and Drucker, D.J. (2000) The glucagon-like peptide-2 receptor mediates direct inhibition of cellular apoptosis via a cAMP-dependent protein kinase-independent pathway. J Biol Chem 275: 35345–52.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • Catherine A Abbott
    • 1
  • Roger Yazbeck
    • 1
    • 2
  • Mark S Geier
    • 2
    • 3
  • Hans-Ulrich Demuth
    • 4
  • Gordon S Howarth
    • 1
    • 2
    • 3
    • 5
    • 6
  1. 1.School of Biological SciencesFlinders UniversityAdelaideAustralia
  2. 2.Centre for Paediatric and Adolescent GastroenterologyWomen’s and Children’s HospitalAdelaideAustralia
  3. 3.Discipline of Physiology, School of Molecular and Biomedical SciencesThe University of AdelaideAustralia
  4. 4.ProbiodrugHalle (Saale)Germany
  5. 5.Department of PaediatricsThe University of AdelaideAustralia
  6. 6.School of Pharmaceutical, Molecular and Biomedical SciencesUniversity of SAAustralia

Personalised recommendations